Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.43 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739158 | 0.85 | RAB9A (0.59) | NPC1RAB9AARLMNAMAPT | |
| SCHEMBL30052305 | 0.84 | NPC1 (0.46) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL8436454 | 0.84 | NPC1 (0.46) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL22169453 | 0.83 | POLB (0.57) | NPC1RAB9AARLMNAMAPT | |
| SCHEMBL1154627 | 0.83 | SQOR (0.45) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL17085521 | 0.82 | KDM4E (0.41) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL5222341 | 0.81 | HTR2A (0.41) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL25202865 | 0.81 | NPC1 (0.39) | NPC1RAB9AHTR2ADRD2HRH1 | |
| SCHEMBL22169493 | 0.80 | RAB9A (0.47) | RAB9AARMAPTSQORL3MBTL1 | |
| SCHEMBL2960326 | 0.80 | NFE2L2 (0.43) | NPC1LMNAMAPTNFE2L2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4727941-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | Lynk Pharmaceuticals Co. Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| US-20260062393-A1 | Compounds | CTXT PTY LTD (AU) | 2026-03-05 | — | — | US | disclosed |
| US-12365655-B2 | Compounds | CTXT PTY LTD (AU) | 2025-07-22 | — | — | US | disclosed |
| CN-112334466-B | Compounds of formula (I) | CTXT私人有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024255885-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-12-19 | — | — | WO | disclosed |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN-LA ROCHE INC. (US) | 2024-11-14 | — | — | US | disclosed |
| CN-114364672-B | Benzisoxazole sulfonamide derivatives | 辉瑞大药厂 | 2024-09-06 | — | — | CN | disclosed |
| EP-4367102-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | F. Hoffmann-La Roche AG (CH) | 2024-05-15 | — | — | EP | disclosed |
| CN-117715892-A | Quaternary ammonium cation substituted compounds for the treatment of bacterial infections | 豪夫迈·罗氏有限公司 | 2024-03-15 | — | — | CN | disclosed |
| EP-4335439-A2 | COMPOUNDS | CTXT PTY LTD (AU) | 2024-03-13 | — | — | EP | disclosed |
| EP-0583317-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1994-02-23 | — | — | EP | disclosed |
| EP-0544488-A2 | Substituted phenyl phenol leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1993-06-02 | — | — | EP | disclosed |
| US-5185027-A | Salicylaldehyde derivatives and salicyclic acid derivatives and their sulfur analogs, and their use as herbicides and bioregulators | BASF AKTIENGESELLSCHAFT (DE) | 1993-02-09 | — | — | US | disclosed |
| WO-1992019607-A1 | DIBENZOTHIAZEPINTHIONE AS ANTIVIRAL AGENTS | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| WO-1992019277-A1 | ANTIVIRAL DIBENZOTHIAZEPINONE DERIVATIVES | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-11-12 | — | — | WO | disclosed |
| EP-0490224-A2 | Derivatives of salicylic aldehyde and salicylic acid, sulfphuranalogs thereof, process and intermediates for their preparation | BASF Aktiengesellschaft (DE) | 1992-06-17 | — | — | EP | disclosed |
| US-5085686-A | Plant growth regulator | BASF AKTIENGESELLSCHAFT (DE) | 1992-02-04 | — | — | US | disclosed |
| EP-0402751-A1 | Derivatives of salicylic aldehyde and salicylic acid and sulphur analoges thereof, methodes for preparing them and their use as herbicides and bioregulators | BASF Aktiengesellschaft (DE) | 1990-12-19 | — | — | EP | disclosed |
| WO-1990001481-A1 | THERAPEUTIC AGENTS | THE BOOTS COMPANY PLC (GB) | 1990-02-22 | — | — | WO | disclosed |
| EP-0354693-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1990-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062393-A1 | Compounds | SCN2B, ABCB11, SCN1B | NPC1 10/4885RAB9A 233/4885HTR2A 678/4885 |
| US-20240376073-A1 | QUATERNARY AMMONIUM CATION SUBSTITUTED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CFTR, HRH1, HRH4 | NPC1 858/4885RAB9A 1520/4885HTR2A 4455/4885 |
| US-12365655-B2 | Compounds | SLC10A1, ABCB11, PCSK9 | NPC1 28/4885RAB9A 419/4885HTR2A 3511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.